Announcements Trials
Browse Landscape

Phase

Phase 1 9Phase 2 7Phase 1/2 4Phase 2/3 2Phase 3 1

Status

Withdrawn 1Unknown 1Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2NIH 1INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Dermatologic 4Gynecologic 1Breast 1

Conditions

Melanoma 53Carcinoma, Non-Small-Cell Lung 50Carcinoma, Renal Cell 32Neoplasms 29Neoplasm Metastasis 24Colorectal Neoplasms 21Carcinoma, Hepatocellular 21Squamous Cell Carcinoma of Head and Neck 18Stomach Neoplasms 16Triple Negative Breast Neoplasms 15Ovarian Neoplasms 14Small Cell Lung Carcinoma 11Pancreatic Neoplasms 11Lung Neoplasms 11Hodgkin Disease 11Carcinoma, Transitional Cell 10Advanced Cancer 9Sarcoma 8Recurrence 8Head and Neck Neoplasms 8Solid Tumor 7Prostatic Neoplasms 7Lymphoma, Non-Hodgkin 7Endometrial Neoplasms 7Uterine Cervical Neoplasms 6Urinary Bladder Neoplasms 6Carcinoma, Merkel Cell 6Breast Neoplasms 6Mesothelioma 5Glioblastoma 5

Interventions

Ipilimumab 5Nivolumab 4pembrolizumab 3sargramostim 2fludarabine 2binimetinib 2aldesleukin 2Interleukin-2 2Granulocyte-Macrophage Colony-Stimulating Factor 2Cyclophosphamide 2trametinib 1tebentafusp 1sotrastaurin 1montanide ISA 51 1incomplete Freund's adjuvant 1glembatumumab vedotin 1fludarabine phosphate 1entrectinib 1Valproic Acid 1Tramadol 1Thalidomide 1Temozolomide 1Solutions 1Ruthenium-106 1Radiotherapy 1RNA, Messenger 1Protein Kinase C 1Melphalan 1Magnetic Resonance Spectroscopy 1Ibuprofen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1/2 × Uveal Melanoma × Nivolumab × Clear all
NCT03686124 2026-05-13

ACTengine

Immatics US, Inc.

Phase 1/2 Recruiting
375 enrolled
DermatologicGynecologic

Uveal Melanoma, Melanoma, Neoplasms, Ovarian Neoplasms, Recurrence

NCT04283890 2025-09-09

CHOPIN

Leiden University Medical Center

Phase 1/2 Active not recruiting
83 enrolled
Dermatologic

Uveal Melanoma, Neoplasm Metastasis

NCT02913417 2021-04-19

Yttrium90, Ipilimumab, & Nivolumab for Uveal Melanoma With Liver Metastases

California Pacific Medical Center Research Institute

Phase 1/2 Unknown
26 enrolled
Dermatologic

Uveal Melanoma

NCT03326258 2018-07-18

Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery

National Cancer Institute (NCI)

Phase 1/2 Withdrawn
BreastDermatologic

Uveal Melanoma, Breast Neoplasms, Melanoma, Neoplasm Metastasis, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡